Nomogram for evaluating obvious liver inflammation in treatment-naïve HBeAg positive chronic hepatitis B virus infection patients with normal ALT

References

• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–10. DOI:10.1007/s12072-015-9675-4
   PubMed Web of Science ®Google Scholar
• Terrault NA, Lok A, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: aASLD 2018 Hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. DOI:10.1002/hep.29800
   PubMed Web of Science ®Google Scholar
• Lampertico P, Agarwal K, Berg T. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398.
   PubMed Web of Science ®Google Scholar
• Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update). J Clin Transl Hepatol. 2017;5(4):297–318. DOI:10.14218/JCTH.2016.00019
   PubMed Web of Science ®Google Scholar
• Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization; 2015 Mar.
   Google Scholar
• [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(12):938–961. DOI:10.3760/cma.j.issn.1007-3418.2019.12.007
   PubMedGoogle Scholar
• BM A. Con: all patients with immune-tolerated hepatitis B virus do not need to be treated. Clin Liver Dis. 2020;15(1):25–30.
   Google Scholar
• [Chinese guidelines on the management of liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2019;27(11):846–865. DOI:10.3760/cma.j.issn.1007-3418.2019.11.008
   PubMedGoogle Scholar
• Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–1984.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang J, Yan X, et al. Presence of liver inflammation in Asian patients with chronic hepatitis B with Normal Alt and Detectable Hbv Dna in Absence of Liver Fibrosis. Hepatol Commun. 2022;6(4):855–866. DOI:10.1002/hep4.1859
   PubMed Web of Science ®Google Scholar
• Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–767.
   PubMed Web of Science ®Google Scholar
• Kim GA, Lim YS, Han S, et al. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut. 2018;67(5):945–952. DOI:10.1136/gutjnl-2017-314904
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Kiriyama S, et al. Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol. 2010;82(4):539–545. DOI:10.1002/jmv.21686
   PubMed Web of Science ®Google Scholar
• Tong MJ, Hsien C, Hsu L, et al. Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States. Hepatology. 2008;48(4):1070–1078.
   PubMed Web of Science ®Google Scholar
• Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B E antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146(5):1240–1248. DOI:10.1053/j.gastro.2014.01.044
   PubMed Web of Science ®Google Scholar
• Wang L, Zou ZQ, Wang K, et al. Role of serum hepatitis B virus marker quantitation to differentiate natural history phases of HBV infection. Hepatol Int. 2016;10(1):133–138.
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Wong GL, et al. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology. 2010;52(4):1232–1241.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508–513. DOI:10.1016/j.jhep.2010.01.007
   PubMed Web of Science ®Google Scholar
• Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;182:104925.
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B E antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis b virus markers. Hepatology. 2010;51(6):1933–1944. DOI:10.1002/hep.23571
   PubMed Web of Science ®Google Scholar
• Zhang L, Li MH, Cao WH, et al. Negative correlation of serum hepatitis B surface antigen and hepatitis B E antigen levels with the severity of liver inflammation in treatment-naïve patients with chronic hepatitis B virus infection. Chin Med J (Engl). 2017;130(22):2697–2702. DOI:10.4103/0366-6999.218000
   PubMed Web of Science ®Google Scholar
• Zhang P, Du HB, Tong GD, et al. Serum hepatitis B surface antigen correlates with fibrosis and necroinflammation: a multicentre perspective in China. J Viral Hepat. 2018;25(9):1017–1025. DOI:10.1111/jvh.12903
   PubMed Web of Science ®Google Scholar
• Zeng DW, Liu YR, Dong J, et al. Serum HbsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection. Mol Med Rep. 2015;11(5):3465–3472. DOI:10.3892/mmr.2015.3207
   PubMed Web of Science ®Google Scholar
• Chen P, Xie Q, Lu X, et al. Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: a community-based study. Medicine (Baltimore). 2017;96(33):E7766. DOI:10.1097/MD.0000000000007766
   PubMed Web of Science ®Google Scholar
• Yang N, Feng J, Zhou T, et al. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients. J Med Virol. 2018;90(7):1240–1245. DOI:10.1002/jmv.25080
   PubMed Web of Science ®Google Scholar
• He P, Zhan J, Tt H, et al. Correlations among serum hepatitis B surface antigen and hepatitis B e antigen titers and viral load in Chinese patients with chronic hepatitis B. Clin Lab. 2015;61(05+06/2015):505–512. DOI:10.7754/Clin.Lab.2014.140914
   PubMedGoogle Scholar
• Cornberg M, Wong VW, Locarnini S, et al. The role of quantitative hepatitis B Surface Antigen Revisited. J Hepatol. 2017;66(2):398–411.
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5(12):1462–1468. DOI:10.1016/j.cgh.2007.09.005
   PubMed Web of Science ®Google Scholar
• Ning Q, Han M, Sun Y, et al. Switching from entecavir to pegifn alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (Osst Trial). J Hepatol. 2014;61(4):777–784. DOI:10.1016/j.jhep.2014.05.044
   PubMed Web of Science ®Google Scholar
• Halfon P, Pénaranda G, Ouzan D. A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success. J Hepatol. 2015;62(1):238.
   PubMed Web of Science ®Google Scholar
• Shin JW, Jung SW, Park BR, et al. Prediction of response to entecavir therapy in patients with hbeag-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels. J Viral Hepat. 2012;19(10):724–731. DOI:10.1111/j.1365-2893.2012.01599.x
   PubMed Web of Science ®Google Scholar
• Lu YF, Li XQ, Han XY, et al. Peripheral blood cell variations in cirrhotic portal hypertension patients with hypersplenism. Asian Pac J Trop Med. 2013;6(8):663–666.
   PubMed Web of Science ®Google Scholar
• Itakura J, Kurosaki M, Setoyama H, et al. Applicability of Apri and Fib-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2021;56(5):470–478. DOI:10.1007/s00535-021-01782-3
   PubMed Web of Science ®Google Scholar
• Chi Z, Zhao W, Li JW, et al. Combination of quantitative hepatitis B core antibody (Qhbcab) and aspartate aminotransferase can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol. 2021;45(6):101563. DOI:10.1016/j.clinre.2020.10.008
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58(2):546–554. DOI:10.1002/hep.26385
   PubMed Web of Science ®Google Scholar
• Cao J, Zhang J, Lu Y, et al. Cryo-Em structure of native spherical subviral particles isolated from hbv carriers. Virus Res. 2019;259:90–96.
   PubMed Web of Science ®Google Scholar
• Pollicino T, Caminiti G. HBV-Integration studies in the clinic: role in the natural history of infection. Viruses. 2021;13(3):368.
   PubMed Web of Science ®Google Scholar
• Wang R, Dai W, Gong J, et al. Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients. J Hematol Oncol. 2022;15(1):11. DOI:10.1186/s13045-022-01225-3
   PubMed Web of Science ®Google Scholar
• Khare S, Arora A, Sharma P, et al. Performance of non-invasive blood parameters for ruling out significant liver fibrosis in patients with chronic hepatitis B. J Clin Transl Hepatol. 2020;8(2):143–149. DOI:10.14218/JCTH.2020.00002
   PubMed Web of Science ®Google Scholar
• Yoshida K, Post G, Shimakawa Y, et al. Clinical utility of treat-B score in African and non-African HBV-infected patients living in Europe. J Hepatol. 2019;70(6):1295–1297. DOI:10.1016/j.jhep.2019.03.008
   PubMed Web of Science ®Google Scholar